Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use
Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence o...
Gespeichert in:
| Veröffentlicht in: | Drug design, development and therapy development and therapy, 2015-01, Vol.9, p.473-485 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 485 |
|---|---|
| container_issue | |
| container_start_page | 473 |
| container_title | Drug design, development and therapy |
| container_volume | 9 |
| creator | Li, Chuan-Jiang Li, Liang |
| description | Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has specific features in Chinese transplant patients; its in vivo pharmacokinetics, treatment regimen, dose and administration, and adverse-effect profile are influenced by multiple factors, such as genetics and the spectrum of primary diseases in the Chinese population. We reviewed the clinical experience of tacrolimus use in Chinese liver- and kidney-transplant patients, including the pharmacology of tacrolimus, the immunosuppressive effects of tacrolimus versus cyclosporine, effects of different factors on tacrolimus metabolism on Chinese patients, personalized medicine, clinical safety profile, and patient satisfaction and adherence. This article provides guidance for the rational and efficient use of tacrolimus in Chinese organ-transplant patients. |
| doi_str_mv | 10.2147/DDDT.S41349 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4298305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A448157504</galeid><sourcerecordid>A448157504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c628t-5cfac93508944b610f871b45e466d1af9a24c5e476d836e26b4ce1f2c3bd13093</originalsourceid><addsrcrecordid>eNqNktuL1DAYxYso7rr65LsMCCJIx9ybvAjLjDdYEHF8Dmn6dSZDm9SkHdC_3pRZd2fEB8lDbr9zknw5RfEcoyXBrHq7Xq83y28MU6YeFJcYV1UppcQPT8YXxZOU9ggJKgh6XFwQLpBShFwWXzfGxtC5fkoL5xdDhAP40fntYozGp6EzflxE2IMdXfAzsto5DwkWgxldRlNZhmF0vfs1i6YET4tHrekSPLvtr4rvH95vVp_Kmy8fP6-ub0oriBxLbltjFeVIKsZqgVErK1wzDkyIBptWGcJsnlWikVQAETWzgFtiad1gihS9Kt4dfYep7qGx-S7RdHqIrjfxpw7G6fMd73Z6Gw6aESUp4tkAHQ2acID88JTOxPerNvQaK8Vplry-PTOGHxOkUfcuWehylSBMSWPBK4qlVPh_UCYkxohk9OVf6D5M0efiaULIbMmJuKe2pgPtfBvyq-xsqq8Zk5hXHLFMLf9B5dZA72zw0Lq8fiZ4dSLYgenGXQrdNH93OgffHMGcl5QitHfVwkjPQdRzEPUxiJl-cfo7d-yf5NHf3M_X8A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2226573526</pqid></control><display><type>article</type><title>Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use</title><source>MEDLINE</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Chuan-Jiang ; Li, Liang</creator><creatorcontrib>Li, Chuan-Jiang ; Li, Liang</creatorcontrib><description>Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has specific features in Chinese transplant patients; its in vivo pharmacokinetics, treatment regimen, dose and administration, and adverse-effect profile are influenced by multiple factors, such as genetics and the spectrum of primary diseases in the Chinese population. We reviewed the clinical experience of tacrolimus use in Chinese liver- and kidney-transplant patients, including the pharmacology of tacrolimus, the immunosuppressive effects of tacrolimus versus cyclosporine, effects of different factors on tacrolimus metabolism on Chinese patients, personalized medicine, clinical safety profile, and patient satisfaction and adherence. This article provides guidance for the rational and efficient use of tacrolimus in Chinese organ-transplant patients.</description><identifier>ISSN: 1177-8881</identifier><identifier>EISSN: 1177-8881</identifier><identifier>DOI: 10.2147/DDDT.S41349</identifier><identifier>PMID: 25609922</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Adenosine triphosphate ; Antigens ; Asian Continental Ancestry Group - genetics ; Biotransformation - genetics ; Calcineurin ; Calcineurin inhibitors ; Calcineurin Inhibitors - adverse effects ; Calcineurin Inhibitors - pharmacokinetics ; Calcineurin Inhibitors - therapeutic use ; China ; Chinese ; Cyclosporins ; Cytokines ; Cytotoxicity ; Dosage and administration ; Drug dosages ; FDA approval ; Fermentation ; Genetics ; Genotype ; Glycoproteins ; Graft rejection ; Graft Rejection - ethnology ; Graft Rejection - prevention & control ; Graft Survival - drug effects ; Health risk assessment ; Humans ; Immunosuppressive agents ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - pharmacokinetics ; Immunosuppressive Agents - therapeutic use ; kidney transplant ; Kidney transplantation ; Kidney Transplantation - adverse effects ; Kidney transplants ; Kidneys ; Liver ; Liver transplantation ; Liver Transplantation - adverse effects ; Liver transplants ; Lymphocytes ; Medication Adherence ; Metabolism ; Patient Satisfaction ; Patients ; Pediatrics ; personalized medicine ; Pharmacogenetics ; Pharmacokinetics ; Pharmacology ; Phenotype ; Phosphatase ; Precision medicine ; Prevention ; Proteins ; Rejection ; Review ; Side effects ; Streptomyces ; Tacrolimus ; Tacrolimus - adverse effects ; Tacrolimus - pharmacokinetics ; Tacrolimus - therapeutic use ; Time Factors ; Transplantation ; Transplants & implants ; Treatment Outcome</subject><ispartof>Drug design, development and therapy, 2015-01, Vol.9, p.473-485</ispartof><rights>COPYRIGHT 2015 Dove Medical Press Limited</rights><rights>2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Li and Li. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c628t-5cfac93508944b610f871b45e466d1af9a24c5e476d836e26b4ce1f2c3bd13093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298305/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298305/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25609922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Chuan-Jiang</creatorcontrib><creatorcontrib>Li, Liang</creatorcontrib><title>Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use</title><title>Drug design, development and therapy</title><addtitle>Drug Des Devel Ther</addtitle><description>Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has specific features in Chinese transplant patients; its in vivo pharmacokinetics, treatment regimen, dose and administration, and adverse-effect profile are influenced by multiple factors, such as genetics and the spectrum of primary diseases in the Chinese population. We reviewed the clinical experience of tacrolimus use in Chinese liver- and kidney-transplant patients, including the pharmacology of tacrolimus, the immunosuppressive effects of tacrolimus versus cyclosporine, effects of different factors on tacrolimus metabolism on Chinese patients, personalized medicine, clinical safety profile, and patient satisfaction and adherence. This article provides guidance for the rational and efficient use of tacrolimus in Chinese organ-transplant patients.</description><subject>Adenosine triphosphate</subject><subject>Antigens</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Biotransformation - genetics</subject><subject>Calcineurin</subject><subject>Calcineurin inhibitors</subject><subject>Calcineurin Inhibitors - adverse effects</subject><subject>Calcineurin Inhibitors - pharmacokinetics</subject><subject>Calcineurin Inhibitors - therapeutic use</subject><subject>China</subject><subject>Chinese</subject><subject>Cyclosporins</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Fermentation</subject><subject>Genetics</subject><subject>Genotype</subject><subject>Glycoproteins</subject><subject>Graft rejection</subject><subject>Graft Rejection - ethnology</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival - drug effects</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - pharmacokinetics</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>kidney transplant</subject><subject>Kidney transplantation</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney transplants</subject><subject>Kidneys</subject><subject>Liver</subject><subject>Liver transplantation</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver transplants</subject><subject>Lymphocytes</subject><subject>Medication Adherence</subject><subject>Metabolism</subject><subject>Patient Satisfaction</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>personalized medicine</subject><subject>Pharmacogenetics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Phenotype</subject><subject>Phosphatase</subject><subject>Precision medicine</subject><subject>Prevention</subject><subject>Proteins</subject><subject>Rejection</subject><subject>Review</subject><subject>Side effects</subject><subject>Streptomyces</subject><subject>Tacrolimus</subject><subject>Tacrolimus - adverse effects</subject><subject>Tacrolimus - pharmacokinetics</subject><subject>Tacrolimus - therapeutic use</subject><subject>Time Factors</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>1177-8881</issn><issn>1177-8881</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNktuL1DAYxYso7rr65LsMCCJIx9ybvAjLjDdYEHF8Dmn6dSZDm9SkHdC_3pRZd2fEB8lDbr9zknw5RfEcoyXBrHq7Xq83y28MU6YeFJcYV1UppcQPT8YXxZOU9ggJKgh6XFwQLpBShFwWXzfGxtC5fkoL5xdDhAP40fntYozGp6EzflxE2IMdXfAzsto5DwkWgxldRlNZhmF0vfs1i6YET4tHrekSPLvtr4rvH95vVp_Kmy8fP6-ub0oriBxLbltjFeVIKsZqgVErK1wzDkyIBptWGcJsnlWikVQAETWzgFtiad1gihS9Kt4dfYep7qGx-S7RdHqIrjfxpw7G6fMd73Z6Gw6aESUp4tkAHQ2acID88JTOxPerNvQaK8Vplry-PTOGHxOkUfcuWehylSBMSWPBK4qlVPh_UCYkxohk9OVf6D5M0efiaULIbMmJuKe2pgPtfBvyq-xsqq8Zk5hXHLFMLf9B5dZA72zw0Lq8fiZ4dSLYgenGXQrdNH93OgffHMGcl5QitHfVwkjPQdRzEPUxiJl-cfo7d-yf5NHf3M_X8A</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Li, Chuan-Jiang</creator><creator>Li, Liang</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use</title><author>Li, Chuan-Jiang ; Li, Liang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c628t-5cfac93508944b610f871b45e466d1af9a24c5e476d836e26b4ce1f2c3bd13093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenosine triphosphate</topic><topic>Antigens</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Biotransformation - genetics</topic><topic>Calcineurin</topic><topic>Calcineurin inhibitors</topic><topic>Calcineurin Inhibitors - adverse effects</topic><topic>Calcineurin Inhibitors - pharmacokinetics</topic><topic>Calcineurin Inhibitors - therapeutic use</topic><topic>China</topic><topic>Chinese</topic><topic>Cyclosporins</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Fermentation</topic><topic>Genetics</topic><topic>Genotype</topic><topic>Glycoproteins</topic><topic>Graft rejection</topic><topic>Graft Rejection - ethnology</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival - drug effects</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - pharmacokinetics</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>kidney transplant</topic><topic>Kidney transplantation</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney transplants</topic><topic>Kidneys</topic><topic>Liver</topic><topic>Liver transplantation</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver transplants</topic><topic>Lymphocytes</topic><topic>Medication Adherence</topic><topic>Metabolism</topic><topic>Patient Satisfaction</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>personalized medicine</topic><topic>Pharmacogenetics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Phenotype</topic><topic>Phosphatase</topic><topic>Precision medicine</topic><topic>Prevention</topic><topic>Proteins</topic><topic>Rejection</topic><topic>Review</topic><topic>Side effects</topic><topic>Streptomyces</topic><topic>Tacrolimus</topic><topic>Tacrolimus - adverse effects</topic><topic>Tacrolimus - pharmacokinetics</topic><topic>Tacrolimus - therapeutic use</topic><topic>Time Factors</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Chuan-Jiang</creatorcontrib><creatorcontrib>Li, Liang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug design, development and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Chuan-Jiang</au><au>Li, Liang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use</atitle><jtitle>Drug design, development and therapy</jtitle><addtitle>Drug Des Devel Ther</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>9</volume><spage>473</spage><epage>485</epage><pages>473-485</pages><issn>1177-8881</issn><eissn>1177-8881</eissn><abstract>Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has specific features in Chinese transplant patients; its in vivo pharmacokinetics, treatment regimen, dose and administration, and adverse-effect profile are influenced by multiple factors, such as genetics and the spectrum of primary diseases in the Chinese population. We reviewed the clinical experience of tacrolimus use in Chinese liver- and kidney-transplant patients, including the pharmacology of tacrolimus, the immunosuppressive effects of tacrolimus versus cyclosporine, effects of different factors on tacrolimus metabolism on Chinese patients, personalized medicine, clinical safety profile, and patient satisfaction and adherence. This article provides guidance for the rational and efficient use of tacrolimus in Chinese organ-transplant patients.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>25609922</pmid><doi>10.2147/DDDT.S41349</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1177-8881 |
| ispartof | Drug design, development and therapy, 2015-01, Vol.9, p.473-485 |
| issn | 1177-8881 1177-8881 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4298305 |
| source | MEDLINE; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adenosine triphosphate Antigens Asian Continental Ancestry Group - genetics Biotransformation - genetics Calcineurin Calcineurin inhibitors Calcineurin Inhibitors - adverse effects Calcineurin Inhibitors - pharmacokinetics Calcineurin Inhibitors - therapeutic use China Chinese Cyclosporins Cytokines Cytotoxicity Dosage and administration Drug dosages FDA approval Fermentation Genetics Genotype Glycoproteins Graft rejection Graft Rejection - ethnology Graft Rejection - prevention & control Graft Survival - drug effects Health risk assessment Humans Immunosuppressive agents Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use kidney transplant Kidney transplantation Kidney Transplantation - adverse effects Kidney transplants Kidneys Liver Liver transplantation Liver Transplantation - adverse effects Liver transplants Lymphocytes Medication Adherence Metabolism Patient Satisfaction Patients Pediatrics personalized medicine Pharmacogenetics Pharmacokinetics Pharmacology Phenotype Phosphatase Precision medicine Prevention Proteins Rejection Review Side effects Streptomyces Tacrolimus Tacrolimus - adverse effects Tacrolimus - pharmacokinetics Tacrolimus - therapeutic use Time Factors Transplantation Transplants & implants Treatment Outcome |
| title | Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A40%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tacrolimus%20in%20preventing%20transplant%20rejection%20in%20Chinese%20patients--optimizing%20use&rft.jtitle=Drug%20design,%20development%20and%20therapy&rft.au=Li,%20Chuan-Jiang&rft.date=2015-01-01&rft.volume=9&rft.spage=473&rft.epage=485&rft.pages=473-485&rft.issn=1177-8881&rft.eissn=1177-8881&rft_id=info:doi/10.2147/DDDT.S41349&rft_dat=%3Cgale_pubme%3EA448157504%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2226573526&rft_id=info:pmid/25609922&rft_galeid=A448157504&rfr_iscdi=true |